Lab Seminar
2024.12.12 저널 발표 (김지호)
작성자
작성일
2025-11-17
조회
129
2024.12.12 저널 발표
발표자: 김지호
발표 논문
Eguren-Santamaria, I., de Piérola, E. F., Camps, G., Martín-Muñoz, P., Campos, M., Cuculescu, D., ... & Sanmamed, M. F. (2024). MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Journal for Immunotherapy of Cancer, 12(9), e008516. PMID: 39244214 PMCID: PMC11381650 DOI: 10.1136/jitc-2023-008516
https://pubmed.ncbi.nlm.nih.gov/39244214/
발표자: 김지호
발표 논문
Eguren-Santamaria, I., de Piérola, E. F., Camps, G., Martín-Muñoz, P., Campos, M., Cuculescu, D., ... & Sanmamed, M. F. (2024). MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Journal for Immunotherapy of Cancer, 12(9), e008516. PMID: 39244214 PMCID: PMC11381650 DOI: 10.1136/jitc-2023-008516
https://pubmed.ncbi.nlm.nih.gov/39244214/